|
PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Posts positive data from a phase 1 trial of its idiopathic pulmonary fibrosis drug candidate LYT-100, or deupirfenidone.
‘This trial supports the dosages that were selected for the Phase 2 trial of LYT-100, which began in June 2022,’ firm explains.
Phase 1 data showed favourable tolerability and safety data. ‘The data from the Phase 1 trial demonstrated that LYT-100 showed a lower incidence of adverse events compared to pirfenidone at comparable exposure levels. LYT-100, or deupirfenidone, is a slightly changed form of pirfenidone.
Current stock price: 246.50 pence,
12-month change: down 30%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
